There is one clinical trial.
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients with mild COVID-19.
Description: Viral loadMeasure: Rate of SARS-CoV-2 eradication at day 14 from study enrollment Time: Hospital day 14
Description: Viral loadMeasure: Rate of SARS-CoV-2 eradication at day 7 from study enrollment Time: Hospital day 7
Description: Viral loadMeasure: Time to SARS-CoV-2 eradication (days) Time: Hospital day 1, 4, 7, 10, 14, 21
Description: Viral load changeMeasure: Viral load area-under-the-curve (AUC) reduction versus control Time: Hospital day 1, 4, 7, 10, 14, 21
Description: Resolution of all systemic and respiratory symptoms for ≥2 consecutive daysMeasure: Time to clinical improvement (days) Time: Up to 28 days
Description: ICU admission, mechanical ventilation or deathMeasure: Proportion of clinical failure Time: Up to 28 days
Description: Number of adverse events, proportion of early discontinuanceMeasure: Safety and tolerability of study drug Time: Up to 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports